Skip to main content

Month: August 2024

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Total 2Q 2024 net product revenue of $87.2 million, representing 87% year-over-year growth Auvelity® 2Q 2024 net product sales of $65.0 million, representing 135% year-over-year growth Sunosi® 2Q 2024 net product revenue of $22.1 million representing 16% year-over-year growth NDA for AXS-07 in migraine resubmitted Topline results of ADVANCE-2 Phase 3 trial of AXS-05 in Alzheimer’s disease agitation anticipated 2H 2024 Topline results of ACCORD-2 Phase 3 randomized withdrawal trial of AXS-05 in Alzheimer’s disease agitation anticipated 2H 2024; target enrollment reached Topline results of FOCUS Phase 3 trial of solriamfetol in ADHD anticipated 2H 2024 SUSTAIN Phase 3 trial of solriamfetol in shift work disorder initiated NDA submission for AXS-14 in fibromyalgia expected 3Q 2024 NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) —...

Continue reading

Investeringsforeningen Sparinvest – Ophævelse af suspension

Under henvisning til Nasdaq Copenhagens regler for udstedere af investeringsbeviser skal ID-Sparinvest, Filial af Sparinvest S.A., Luxembourg hermed på vegne af de berørte afdelinger i Investeringsforeningen Sparinvest offentliggøre, at der igen kan foretages be­regning af indre værdier for de berørte afdelinger. De indre værdier vil blive indberettet til Nasdaq Copenhagen. Suspension af handel med de berørte afdelingerne ophæves hermed. De berørte afdelinger fremgår af tabellen nendenfor.Order Book Code Afdelingsnavn ISINSPIVEMKLA Value Emerging Markets KL A DK0010304856SPIEMIKL INDEX Emerging Markets KL DK0060300762SPIBJAKL INDEX Bæredygtige Japan KL DK0010297977Henvendelser vedrørende nærværende fondsbørsmeddelelse kan rettes til npa.pm@nykredit.dk cc jna@nykredit.dk.Med venlig hilsenDirk Schulze

Continue reading

Freshpet, Inc. Reports Second Quarter 2024 Financial Results

Significant Profitability and Operating Cash Flow Improvement Second Quarter 2024 Net Sales Driven Entirely by Volume Growth Company Raises 2024 Net Sales and Adjusted EBITDA Guidance BEDMINSTER, N.J., Aug. 05, 2024 (GLOBE NEWSWIRE) — Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Compared to Prior Year PeriodNet sales of $235.3 million, an increase of 28.3%. Net loss of $1.7 million, compared to the prior year period net loss of $17.0 million. Gross margin of 39.9%, compared to the prior year period of 32.3%. Adjusted Gross Margin of 45.9%, compared to the prior year period of 39.8%.1 Adjusted EBITDA of $35.1 million, compared to the prior year period of $9.0 million.1“Freshpet is delivering...

Continue reading

Verano to Welcome Ohio Adult Use Cannabis Customers on August 6th at Company’s Zen Leaf Dispensaries to Commemorate Historic End of Cannabis Prohibition in the Buckeye State

Company Also Confirms Sixth Ohio Zen Leaf Dispensary Location in Antwerp – Near Indiana Border and City of Ft. Wayne, IN – Will Open in Near Future CHICAGO, Aug. 05, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that after obtaining all required approvals, the Company will commence adult use cannabis sales in Ohio on Tuesday, August 6th at four of its five statewide Zen Leaf retail locations in Bowling Green, Canton, Cincinnati, and Dayton, with its Newark location expected to follow pending approval from state officials. Established in 2018, Verano’s Ohio operations also include a state-of-the-art 22,000 square foot cultivation and processing facility in Canton. Verano will also open a sixth Zen Leaf...

Continue reading

Carlyle Secured Lending, Inc. Announces Financial Results For Second Quarter Ended 2024, Declares Third Quarter 2024 Dividends of $0.47 Per Common Share and Announces Merger Agreement with Carlyle Secured Lending III

NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) — Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, “we,” “us,” “our,” “CGBD” or the “Company”) (NASDAQ: CGBD) today announced its financial results for its second quarter ended June 30, 2024. Justin Plouffe, CGBD’s Chief Executive Officer said, “Our core middle-market strategy and active approach to portfolio management continued to drive strong performance in the second quarter of 2024, as we maintained a dynamic approach to origination in an increasingly competitive market. With increased volume during the quarter, we capitalized on attractive origination opportunities, and we see the potential for increased deal activity through year-end. Overall, we remain pleased with our results and look forward to continuing to deliver the consistent income and returns our...

Continue reading

BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update

Announced positive data from multiple mRNA cancer vaccine clinical trials, including topline results from the ongoing Phase 2 evaluating FixVac candidate BNT111 Launched updated variant-adapted COVID-19 vaccine in the European Union (“EU”), received approval in the United Kingdom and initiated rolling supplemental Biologics Licensing Application (“sBLA”) with the United States Food and Drug Administration (“U.S. FDA”) Reiterates guidance for total revenues in the range of €2.5-3.1 billion Reports second quarter 2024 revenues of €128.7 million, net loss of €807.8 million and loss per share of €3.36 ($3.621) Invested €525.6 million or approximately 90% of the Company’s total R&D spend in Q2 in non-COVID-19 related activities, mainly oncology and mRNA; investments are in line with the reiterated full-year R&D expense guidance Ended...

Continue reading

Genmab Takes Full Control of Acasunlimab Development Program

Company AnnouncementGenmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not to participate in the further development of the acasunlimab program under the parties’ existing collaboration agreement The overall collaboration between the companies to continue unchangedCOPENHAGEN, Denmark; August 5, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it will assume sole responsibility for the continued development and potential commercialization of acasunlimab. BioNTech SE (BioNTech) has opted not to participate in the further development of the acasunlimab program under the parties’ existing collaboration agreement. The program will be subject to payment of certain milestones and a tiered single-digit royalty on net sales by Genmab to BioNTech. Genmab...

Continue reading

Share buyback programme – week 31

Nasdaq CopenhagenEuronext DublinLondon Stock ExchangeOther stakeholders Date        5 August 2024 Share buyback programme – week 31 The share buyback programme runs in the period 1 February 2024 up to and including 27 January 2025, see company announcement of 31 January 2024. Part I of the programme, for DKK 750 million, was completed on 27 June 2024, see company announcement of 28 June 2024. Part II of the programme, for DKK 775 million and a maximum of 1,550,000 shares, is for execution in the period 28 June 2024 – 27 January 2025. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” rules. The following transactions have been made under the programme:Date Number...

Continue reading

Shareholding as 07/31/2024

INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES Declaration pursuant to Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des marchés financiers (AMF)Date of settlementof information Total number of shares Number of shares without voting rights (*) Number of voting rights for threshold calculation (**) Number of actual voting rights (exercisable at shareholders’ meeting)July 31, 2024 20 455 403 818 150 22 352 336 21 534 186June 30, 2024 20 455 403 813 392 22 352 340 21 538 948May 31, 2024 20 455 403 758 861 22 374 878 21 616 017April 30, 2024 20 455 403 714 864 22 375 860 21 660 996March 31, 2024 20 455 403 696 391 22 376 742 21 680 351February 29, 2024 20 455 403 700 847 22 376 636 21 675 789January 31, 2024 20 455 403 697 328 22 376 636 21 679...

Continue reading

cBrain Signs Contract on Ambitious AI Transformation Project in the UAE

Press Release no. 07/2024 cBrain Signs Contract on Ambitious AI Transformation Project in the UAECopenhagen, August 5, 2024cBrain (NASDAQ: CBRAIN) has signed a contract to enter a new partnership, supporting an agency in the United Arab Emirates with their AI-driven digital transformation. For cBrain, this is an important next step in the Emirates, initiating the first project within the area of climate software for government. Denmark ranks number one in the United Nations global e-government index, and as a leading supplier to the Danish government, cBrain has provided the core digital platform for the Danish Environmental Protection Agency based on F2. cBrain thereby brings both solid experience in government digitization and insight into government processes related to climate action and the environment. As part of the partnership,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.